99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA
Phase II and III Clinical Trials 3: Blood, Lung, Brain/CNS, and Sarcoma: Poster Presentations - Proffered Abstracts
Multi-lineage response to a combination of gingerol and curcumin in low risk myelodysplastic syndromes (MDS).
Talaha Ali and
Saint Vincent's Comprehensive Cancer Center, New York, NY, University of Massachusetts Medical Center, Worcester, MA
Management of lower risk MDS patients who are still transfusion-independent has not been extensively examined, therapy being typically withheld until patients either become transfusion-dependent or show signs of disease progression. Low intensity therapies could be tried in these patients for two potential benefits; to improve the cytopenias and to determine of intervention at this early stage could arrest and/or reverse the expansion of the abnormal clone. We combined curcumin, the major active ingredient of the spice turmeric, which interferes with a host of cell signals and has anti-cancer, anti-proliferative, anti-inflammatory, anti-angiogenic and anti-oxidant properties, with gingerol, the active constituent of ginger, which is anti-leukemic, anti-bcl-2, inhibits EGF-induced transformation and prevents the development of colon cancer cells, to treat 9 patients with low or Int-1 risk MDS on a clinical trial. Curcumin was administered in an incremental dosing schedule starting with 2.0 Gm in 4 divided doses/day, increasing to 8 Gm/day and Gingerol 350mg bid increasing to 1.4Gm/day (supplied by Sami Labs, NJ). The high dose of ginger-curcumin has been very well tolerated with little or no side effects. The preliminary results have been very encouraging. Patients have been followed for 4-18 months and included 7 males and 2 females with 6 RA, 2 RARS, and 1 unclassified. One patient has been lost to follow-up, 2 are too early for response evaluation (done every six months), but of the 6 remaining patients 4 have shown overall hematologic improvement (HI) with 3 showing trilineage improvement. Two patients had stable disease.
In conclusion, the curcumin/gingerol combination is well tolerated and potentially beneficial for early stage MDS patients who are not transfusion dependent.